Renal-cell carcinoma is an immunogenic malignancy, since (i) tumors are rich in lymphocytes infiltrates, (ii), spontaneous tumor regression may occur spontaneously, and (iii) earlier administration of immunotherapy (interleukin 2, interferon alpha) has proven effective in a subset of patients, with complete tumor regression observed at high doses despite, unfortunately, a significant rate of toxicities [26,27,28]. Here, IL2 is linked to neoplasm.